INDIANAPOLIS, Oct. 9, 2015 /PRNewswire/ -- Eli Lilly and
Company (NYSE: LLY) today announced plans to add 30,000 square feet
and approximately 50 new jobs to its research and development
presence at the Alexandria Center for Life Science in
New York, New York.
Upon completion in 2016, this space will include a translational
immuno-oncology hub and a Lilly "portal," which will provide local
academic scientists with opportunities for collaborative access to
cutting-edge drug discovery capabilities, including chemistry and
lead optimization expertise.
"Going forward, immuno-oncology research will focus on new ways
to harness the immune system and on combination therapies with
targeted agents," said Jan Lundberg,
Ph.D., executive vice president of science and technology and
president of Lilly Research Laboratories. "Cancer is a complex
disease. Our diverse research approach and expansion in
New York will ultimately put us in
a strong position to advance the delivery of innovative medicines
to patients."
The expansion will allow Lilly to strengthen its relationships
with local academic institutions and prominent medical schools.
Increased collaboration will help expedite the discovery and
development of new medicines in Lilly's key therapeutic areas,
including oncology, diabetes and related complications,
neurodegeneration, immunology and pain.
"We are prepared to push the boundaries to accelerate drug
discovery," said Lundberg. "Our expanded capabilities at the
New York site will further Lilly's
expertise in our core therapeutic areas and help pave the way for
broader collaboration with leading academic, health care and
industry colleagues."
This is Lilly's third strategic research and development
expansion this year with a focus on internal and external
collaborations. In May, Lilly announced it would build a delivery
and device innovation center in Cambridge, Massachusetts. In July, Lilly
announced an expansion of its biotechnology center in San Diego, California.
Lilly initially entered the New
York and New Jersey area
with the acquisition of ImClone in 2008. In 2010, Lilly opened its
research and development site at the Alexandria Center for Life
Science, which is located near the East River in New York. Lilly also has a manufacturing and
clinical development center in Bridgewater, New Jersey.
About Eli Lilly and Company
Lilly is a global
healthcare leader that unites caring with discovery to make life
better for people around the world. We were founded more than a
century ago by a man committed to creating high-quality medicines
that meet real needs, and today we remain true to that mission in
all our work. Across the globe, Lilly employees work to discover
and bring life-changing medicines to those who need them, improve
the understanding and management of disease, and give back to
communities through philanthropy and volunteerism. To learn more
about Lilly, please visit us at www.lilly.com and
newsroom.lilly.com/social-channels. C-LLY
About the Alexandria Center for Life Science –
New York City
The
Alexandria Center for Life Science, developed by Alexandria Real
Estate Equities, Inc. (NYSE: ARE), is New York City's first and only collaborative
urban campus for life science companies at the forefront of
innovation. With mission-critical adjacency to world-renowned
academic and medical institutions, the Alexandria Center provides
client tenants with access to an unmatched concentration of
scientific, clinical and entrepreneurial talent; top-tier
investment capital; and a diverse and innovative commercial life
science industry. The approximately 730,000 RSF iconic urban campus
features a highly collaborative and dynamic environment with
creative amenities designed to foster innovation and drive
productivity, including a state-of-the-art digital conference
center and event space; two culinary establishments; an
award-winning urban farm; a fully integrated fitness center; and a
waterfront esplanade. The Alexandria Center for Life Science has
become New York City's leading
destination for the most innovative life science entities to
translate novel discoveries into breakthrough products for patients
around the world. To learn more about Alexandria, please visit www.are.com.
Refer to:
Jackie Shelton; sheltonj@lilly.com;
317-719-5928
Amy Sousa; amy.sousa@lilly.com;
317-997-1481
Logo - http://photos.prnewswire.com/prnh/20031219/LLYLOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/eli-lilly-and-company-expands-new-york-city-research-and-development-site-300156541.html
SOURCE Eli Lilly and Company